Related Experiment Video
Updated: Nov 23, 2025

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Making a case "for" focal therapy of the prostate in intermediate risk prostate cancer: current perspective and
Alex Z Wang1, Amir H Lebastchi2,3, Luke P O'Connor1
1Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Abstract:
Focal therapy is growing as an alternative management options for men with clinically localized prostate cancer. Parallel to the increasing popularity of active surveillance (AS) as a treatment for low-risk disease, there has been an increased interest towards providing focal therapy for patients with intermediate-risk disease. Focal therapy can act as a logical "middle ground" in patients who seek treatment while minimizing potential side effects of definitive whole-gland treatment. The aim of the current review is to define the rationale of focal therapy in patients with intermediate-risk prostate cancer and highlight the importance of patient selection in focal therapy candidacy.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Clinical Trials: Overview

